Guest
Guest
Powerfull research based Formula over 3 years in the market place.CONTEST!
PowerFULL A deep look at Dolichos Pruriens ingredient
by Kenton Engel
PureDOPA is a scientifically-balanced matrix containing a very particular extract of Dolichos Pruriens L., an L-DOPA containing compound that, combined with other constituents, vastly outperforms synthetic L-DOPA with 110% higher peak concentrations, 165% longer peak concentrations, and an onset time around 50% shorter [1]. L-DOPA’s action as it pertains to the release of endogenous growth hormone, then, is the transient increase in the peptide responsible for Growth Hormone release – GHRH (growth hormone releasing hormone). Like L-DOPA, Mucuna Prurien’s postulated manner of increasing the activity of the Dopaminergic-Pituitary-GH release axis is through the potentiation of the cortico-basal ganglion complex, including the most prominent areas of Dopamine production and distribution (Substantia nigra, primarily). And like synthetic preparations of L-DOPA, research has reflected that the Substantia Nigra (the part of mid-brain containing the majority of Dopamine-producing ions) need not be in a degraded state to illicit to prominent GH induction, but rather, effects of oral L-DOPA administration have been noted in healthy, normal patients [3, 4, 15]. In fact, a transient endogenous growth hormone of 500% was in fact seen in a particular work [11], while an average increase of 221% in non-pathological state [i.e., healthy] participants was seen in another [14]. As stated, research has shown that this increase is most likely occurring by way of LD-induced hypothalamtic GHRH (growth hormone releasing hormone) production [2, 4].
As has been state, it should be readily noted that the increases of plasma GHRH and GH [1,2,3,4] have been noted as a result of synthetic L-DOPA administration. However, Dolichos P.L., not only contains natural sources of L-DOPA, with demonstrated efficacy at raising L-DOPA (with its subsequent effect on GHRH and GH) of twice to three times that of synthetic L-DOPA [1, 6, 7], but also most likely contains independent L-DOPA enhancing adjuvents, or possibly inherent decarboxylase inhibitors [6. 7. 8]. The latter scenario is likely as Dopamine and its metabolites have not been found in the nigrostriatal tract after Mucuna administration [8], as well as a lack of dyskensia in Parkinson’s patients [1] and lack of side-effects in normal patients [3]. This data is indicative of a lack of Dopaminergic transmission in peripheral tissues.
The final point of concern relative to L-DOPA, and therefore Dolichos P.L., is long-term safety and tolerability concerns associated with synthetic L-DOPA administration. Synthetic L-DOPA has been noted to have many adverse side-effects including hypertension, dyskenisia (uncontrollable movement), dizziness, nausea, and so on. However, Dolichos has not shown these same side-effects in Parkinson’s patients [1], and L-DOPA administration has not displayed these same side-effects in healthy, normal subjects [2, 3].
Along with the above side-effects, synthetic L-DOPA has been shown to have damaging effects to dopamine ions in the region of the brain most responsible for dopamine transmission (the substantia nigra). This can lead to an aggregate decrease in endogenous dopamine production; however, DLP has displayed neuro-restorative effects in the relevant data, increasing levels of serotonin, dopamine, levadopa, and norepinephrine [9]. This is most likely due to a more efficient transmission of dopamine, and Mucuna containing NADH and COQ-10, both powerfull neurorestorative compounds [9. 10].
Finally, recent studies have also found that Mucuna pruriens Linn. Produced a significant and sustained increase in sexual activity in normal male rats; additionally, in infertile men, it was able to increase Luteinzing Hormone (LH) levels close to 23-41% while also increasing total testosterone by approximately 27-39% [13]; it was also able to decrease prolactin levels by 11-32%. [13] The authors of the studies believe that these beneficial effects may be, at least in part, due to the decrease in prolactin levels and a general decrease in cortisol and stress. Specifically, they believe that the elevated cortisol levels seen with stress can, over an extended period of time, lead to a decrease in testosterone production, while at the same time; elevated prolactin in men may also decrease signaling from the brain to produce testosterone as well. The plant Mucuna pruriens appears to counteract these detrimental changes. This cortisol-attenuating capacity, coupled with L-DOPA mediated hypersexuality [12], may also explain why MP is regarded, anecdotally, as having a marked virility-inducing capacity.
PowerFULL A deep look at Dolichos Pruriens ingredient
by Kenton Engel
PureDOPA is a scientifically-balanced matrix containing a very particular extract of Dolichos Pruriens L., an L-DOPA containing compound that, combined with other constituents, vastly outperforms synthetic L-DOPA with 110% higher peak concentrations, 165% longer peak concentrations, and an onset time around 50% shorter [1]. L-DOPA’s action as it pertains to the release of endogenous growth hormone, then, is the transient increase in the peptide responsible for Growth Hormone release – GHRH (growth hormone releasing hormone). Like L-DOPA, Mucuna Prurien’s postulated manner of increasing the activity of the Dopaminergic-Pituitary-GH release axis is through the potentiation of the cortico-basal ganglion complex, including the most prominent areas of Dopamine production and distribution (Substantia nigra, primarily). And like synthetic preparations of L-DOPA, research has reflected that the Substantia Nigra (the part of mid-brain containing the majority of Dopamine-producing ions) need not be in a degraded state to illicit to prominent GH induction, but rather, effects of oral L-DOPA administration have been noted in healthy, normal patients [3, 4, 15]. In fact, a transient endogenous growth hormone of 500% was in fact seen in a particular work [11], while an average increase of 221% in non-pathological state [i.e., healthy] participants was seen in another [14]. As stated, research has shown that this increase is most likely occurring by way of LD-induced hypothalamtic GHRH (growth hormone releasing hormone) production [2, 4].
As has been state, it should be readily noted that the increases of plasma GHRH and GH [1,2,3,4] have been noted as a result of synthetic L-DOPA administration. However, Dolichos P.L., not only contains natural sources of L-DOPA, with demonstrated efficacy at raising L-DOPA (with its subsequent effect on GHRH and GH) of twice to three times that of synthetic L-DOPA [1, 6, 7], but also most likely contains independent L-DOPA enhancing adjuvents, or possibly inherent decarboxylase inhibitors [6. 7. 8]. The latter scenario is likely as Dopamine and its metabolites have not been found in the nigrostriatal tract after Mucuna administration [8], as well as a lack of dyskensia in Parkinson’s patients [1] and lack of side-effects in normal patients [3]. This data is indicative of a lack of Dopaminergic transmission in peripheral tissues.
The final point of concern relative to L-DOPA, and therefore Dolichos P.L., is long-term safety and tolerability concerns associated with synthetic L-DOPA administration. Synthetic L-DOPA has been noted to have many adverse side-effects including hypertension, dyskenisia (uncontrollable movement), dizziness, nausea, and so on. However, Dolichos has not shown these same side-effects in Parkinson’s patients [1], and L-DOPA administration has not displayed these same side-effects in healthy, normal subjects [2, 3].
Along with the above side-effects, synthetic L-DOPA has been shown to have damaging effects to dopamine ions in the region of the brain most responsible for dopamine transmission (the substantia nigra). This can lead to an aggregate decrease in endogenous dopamine production; however, DLP has displayed neuro-restorative effects in the relevant data, increasing levels of serotonin, dopamine, levadopa, and norepinephrine [9]. This is most likely due to a more efficient transmission of dopamine, and Mucuna containing NADH and COQ-10, both powerfull neurorestorative compounds [9. 10].
Finally, recent studies have also found that Mucuna pruriens Linn. Produced a significant and sustained increase in sexual activity in normal male rats; additionally, in infertile men, it was able to increase Luteinzing Hormone (LH) levels close to 23-41% while also increasing total testosterone by approximately 27-39% [13]; it was also able to decrease prolactin levels by 11-32%. [13] The authors of the studies believe that these beneficial effects may be, at least in part, due to the decrease in prolactin levels and a general decrease in cortisol and stress. Specifically, they believe that the elevated cortisol levels seen with stress can, over an extended period of time, lead to a decrease in testosterone production, while at the same time; elevated prolactin in men may also decrease signaling from the brain to produce testosterone as well. The plant Mucuna pruriens appears to counteract these detrimental changes. This cortisol-attenuating capacity, coupled with L-DOPA mediated hypersexuality [12], may also explain why MP is regarded, anecdotally, as having a marked virility-inducing capacity.
